File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.23822/EurAnnACI.1764-1489.47
- Scopus: eid_2-s2.0-85056262333
- PMID: 29384118
- WOS: WOS:000449302100005
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Paediatric case series of drug reaction with eosinophilia and systemic symptoms (dress): 12-year experience at a single referral centre in Hong Kong and the first reported use of infliximab
Title | Paediatric case series of drug reaction with eosinophilia and systemic symptoms (dress): 12-year experience at a single referral centre in Hong Kong and the first reported use of infliximab |
---|---|
Authors | |
Keywords | Paediatric Drug reaction with eosinophilia and systemic symptoms DRESS Drug-induced hypersensitivity syndrome Chinese Hong Kong |
Issue Date | 2018 |
Publisher | Mattioli 1885 SpA. The Journal's web site is located at http://www.eurannallergyimm.com/ |
Citation | European Annals of Allergy and Clinical Immunology, 2018, v. 50 n. 6, p. 273-276 How to Cite? |
Abstract | DRESS (drug reaction with eosinophilia and systemic symptoms) is a rare but potentially life-threatening disorder characterized by fever, skin eruption, haematological abnormalities and multi-organ dysfunction after drug exposure. The pathophysiology is thought to be related to interactions between culprit drugs, viral reactivation and T-lymphocytes activation. We report 4 paediatric patients with DRESS who were treated at our centre over the past 12 years. Most cases improved after corticosteroids. Other immunosuppressive medications were attempted in refractory cases with varied outcomes. Patient 3 was the first reported case that involved the use of infliximab, a TNF-α inhibitor, for DRESS. Although clinical efficacy was not observed for this one patient, a previous study demonstrated that patients with DRESS, disease progression and HHV-6 reactivation had elevated pre-treatment TNF- α and IL-6 levels. Further research is needed to explore the role of these cytokines in DRESS. |
Persistent Identifier | http://hdl.handle.net/10722/261836 |
ISSN | 2023 Impact Factor: 2.6 2023 SCImago Journal Rankings: 0.521 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chua, GT | - |
dc.contributor.author | Sou Da Rosa Duque, J | - |
dc.contributor.author | Chong, CY | - |
dc.contributor.author | Lee, PPW | - |
dc.contributor.author | Lau, YL | - |
dc.contributor.author | Ho, MHK | - |
dc.date.accessioned | 2018-09-28T04:48:55Z | - |
dc.date.available | 2018-09-28T04:48:55Z | - |
dc.date.issued | 2018 | - |
dc.identifier.citation | European Annals of Allergy and Clinical Immunology, 2018, v. 50 n. 6, p. 273-276 | - |
dc.identifier.issn | 1764-1489 | - |
dc.identifier.uri | http://hdl.handle.net/10722/261836 | - |
dc.description.abstract | DRESS (drug reaction with eosinophilia and systemic symptoms) is a rare but potentially life-threatening disorder characterized by fever, skin eruption, haematological abnormalities and multi-organ dysfunction after drug exposure. The pathophysiology is thought to be related to interactions between culprit drugs, viral reactivation and T-lymphocytes activation. We report 4 paediatric patients with DRESS who were treated at our centre over the past 12 years. Most cases improved after corticosteroids. Other immunosuppressive medications were attempted in refractory cases with varied outcomes. Patient 3 was the first reported case that involved the use of infliximab, a TNF-α inhibitor, for DRESS. Although clinical efficacy was not observed for this one patient, a previous study demonstrated that patients with DRESS, disease progression and HHV-6 reactivation had elevated pre-treatment TNF- α and IL-6 levels. Further research is needed to explore the role of these cytokines in DRESS. | - |
dc.language | eng | - |
dc.publisher | Mattioli 1885 SpA. The Journal's web site is located at http://www.eurannallergyimm.com/ | - |
dc.relation.ispartof | European Annals of Allergy and Clinical Immunology | - |
dc.subject | Paediatric | - |
dc.subject | Drug reaction with eosinophilia and systemic symptoms | - |
dc.subject | DRESS | - |
dc.subject | Drug-induced hypersensitivity syndrome | - |
dc.subject | Chinese | - |
dc.subject | Hong Kong | - |
dc.title | Paediatric case series of drug reaction with eosinophilia and systemic symptoms (dress): 12-year experience at a single referral centre in Hong Kong and the first reported use of infliximab | - |
dc.type | Article | - |
dc.identifier.email | Chua, GT: cgt560@hku.hk | - |
dc.identifier.email | Sou Da Rosa Duque, J: jsrduque@hku.hk | - |
dc.identifier.email | Chong, CY: chongpcy@hku.hk | - |
dc.identifier.email | Lee, PPW: ppwlee@hku.hk | - |
dc.identifier.email | Lau, YL: lauylung@hku.hk | - |
dc.identifier.email | Ho, MHK: marcoho@hku.hk | - |
dc.identifier.authority | Sou Da Rosa Duque, J=rp02340 | - |
dc.identifier.authority | Lee, PPW=rp00462 | - |
dc.identifier.authority | Lau, YL=rp00361 | - |
dc.description.nature | link_to_OA_fulltext | - |
dc.identifier.doi | 10.23822/EurAnnACI.1764-1489.47 | - |
dc.identifier.pmid | 29384118 | - |
dc.identifier.scopus | eid_2-s2.0-85056262333 | - |
dc.identifier.hkuros | 292818 | - |
dc.identifier.volume | 50 | - |
dc.identifier.issue | 6 | - |
dc.identifier.spage | 273 | - |
dc.identifier.epage | 276 | - |
dc.identifier.isi | WOS:000449302100005 | - |
dc.publisher.place | Italy | - |
dc.identifier.issnl | 1764-1489 | - |